meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs Standard of Care (SoC)
vs non active control
vs placebo
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
deaths (OS)
mGC or mGEJC - L2 - all population
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
versus paclitaxel
pembrolizumab alone vs. paclitaxel
1
certainty unassessable
-6%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open